OWP Pharmaceuticals And EVERSANA Announce Partnership To Commercialize Oral Liquid Formulations To Treat Neuroscience Disorders

OWP Pharmaceuticals, Inc. is a privately held, neuroscience specialty pharmaceutical company, dedicated to developing and commercializing novel oral liquid formulations and supporting global philanthropy. OWP announced its partnership with EVERSANA™, the pioneer of next generation commercial services to the global life sciences industry, to launch and commercialize its portfolio of oral liquid formulations aimed to treat neuroscience disorders.

CES 2022 News: Vuzix and TeamViewer to Jointly Demonstrate Frontline AR Platform for Connected Workers at CES 2022

Pending regulatory approvals, OWP has multiple specialty pharmaceutical products in development. Most recently, OWP announced IND authorization for the first-ever oral liquid formulation of atomoxetine hydrochloride for the treatment of attention deficit hyperactivity disorder. OWP has also received patent issuance or IND authorization for multiple therapies for the treatment of epilepsy, schizophrenia, bipolar disorder, major depressive and generalized anxiety disorder, and migraines.

OWP will utilize many of EVERSANA’s fully integrated commercialization services that include market access, agency services, clinical and commercial field teams, channel management, patient services, health economics and outcomes research, and compliance, with each service optimized by data and predictive analytics.

Recommended AI News: IAS Acquires AI Company, Context, to Further Enhance Image and Video Classification

“With EVERSANA’s integrated commercialization solution, we are ensuring that our products will get to patients efficiently and effectively as we anticipate multiple regulatory approvals in 2023 and beyond,” said Scott Boyer, Founder and President, OWP.

“The unmet need for better neuroscience treatments demands our attention,” said Jim Lang, Chief Executive Officer of EVERSANA. “Our EVERSANA COMPLETE end-to-end commercialization engine will be ready to move swiftly in anticipation of FDA submissions and approvals.

“

Established in 2014, OWP Pharmaceuticals’ focus is to support patients and healthcare providers in neurology and psychiatry in the U.S. with beneficial neuroscience medications, and to donate profits to the ROW Foundation ROW seeks to improve the education, diagnosis, and treatment available for those living with neurological and psychiatric disorders in under-resourced areas of the world.

Recommended AI News: Aetion Acquires Synthetic Data Trailblazer Replica Analytics

[To share your insights with us, please write to sghosh@martechseries.com]